The estimated Net Worth of Sara Bonstein is at least $28 Million dollars as of 28 May 2024. Ms Bonstein owns over 241,288 units of Insmed Inc stock worth over $26,104,032 and over the last 11 years she sold INSM stock worth over $1,187,211. In addition, she makes $697,715 as Chief Financial Officer at Insmed Inc.
Sign up
Ms MBA INSM stock SEC Form 4 insiders trading
Ms has made over 15 trades of the Insmed Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently she exercised 241,288 units of INSM stock worth $6,406,196 on 28 May 2024.
The largest trade she's ever made was exercising 241,288 units of Insmed Inc stock on 28 May 2024 worth over $6,406,196. On average, Ms trades about 3,642 units every 34 days since 2014. As of 28 May 2024 she still owns at least 358,769 units of Insmed Inc stock.
You can see the complete history of Ms Bonstein stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Ms. Sara M. Bonstein MBA biography
Sara M. Bonstein MBA is the Chief Financial Officer at Insmed Inc.
What is the salary of Ms MBA?
As the Chief Financial Officer of Insmed Inc, the total compensation of Ms MBA at Insmed Inc is $697,715. There are 9 executives at Insmed Inc getting paid more, with William Lewis having the highest compensation of $7,175,090.
How old is Ms MBA?
Ms MBA is 40, she's been the Chief Financial Officer of Insmed Inc since . There are 22 older and 1 younger executives at Insmed Inc. The oldest executive at Insmed Inc is Steinar Engelsen, 70, who is the Independent Director.
What's Ms MBA's mailing address?
Sara's mailing address filed with the SEC is C/O SCPHARMACEUTICALS INC, 25 BURLINGTON MALL ROAD, SUITE 203, BURLINGTON, MA, 01803.
Insiders trading at Insmed Inc
Over the last 22 years, insiders at Insmed Inc have traded over $46,121,705 worth of Insmed Inc stock and bought 1,080,212 units worth $8,226,993 . The most active insiders traders include Llc Fmr, William Lewis, and Dennis M Lanfear. On average, Insmed Inc executives and independent directors trade stock every 38 days with the average trade being worth of $2,452,158. The most recent stock trade was executed by Orlov S Nicole Schaeffer on 10 September 2024, trading 37,575 units of INSM stock currently worth $407,689.
What does Insmed Inc do?
insmed is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. the company is dedicated to developing and bringing to market therapies that make a real difference in patients’ lives, while striving to understand and enhance the entire patient experience, from diagnosis and treatment to everyday living. headquartered in bridgewater, nj, we are a rapidly growing company with offices in seven countries.
What does Insmed Inc's logo look like?
Complete history of Ms Bonstein stock trades at Ayala Pharmaceuticals, Insmed Inc, OncoSec Medical Inc, and scPharmaceuticals Inc
Insmed Inc executives and stock owners
Insmed Inc executives and other stock owners filed with the SEC include:
-
William Lewis,
Chairman of the Board, President, Chief Executive Officer -
Roger Adsett,
Chief Operating Officer -
Christine Pellizzari,
Chief Legal Officer -
S. Nicole Schaeffer,
Chief People Strategy Officer -
William H. Lewis J.D., M.B.A.,
Pres, CEO & Chairman -
Dr. Martina Flammer M.B.A., M.D.,
Chief Medical Officer -
John Goll,
Chief Accounting Officer -
Roger Adsett,
Chief Operating Officer -
Christine A. Pellizzari J.D.,
Consultant -
Sara M. Bonstein MBA,
Chief Financial Officer -
John Goll III,
Sr. VP & Chief Accounting Officer -
David Brennan,
Lead Independent Director -
Alfred Altomari,
Independent Director -
Steinar Engelsen,
Independent Director -
David McGirr,
Independent Director -
Melvin Sharoky,
Independent Director -
Leo Lee,
Independent Director -
Elizabeth Anderson,
Independent Director -
Clarissa Desjardins,
Independent Director -
Carol Schafer,
Director -
Martina Flammer,
Chief Medical Officer -
John Soriano,
Chief Compliance Officer -
Sara Bonstein,
Chief Financial Officer -
S. Nicole Schaeffer,
Chief People Strategy Officer -
Mandy Fahey,
Sr. Director of Corp. Communications -
Michael Alexander Smith,
Sr. VP & Gen. Counsel -
John D. Soriano J.D.,
Chief Compliance Officer -
Eleanor Barisser,
Associate Director of Investor Relations -
Paolo Tombesi,
Chief Financial Officer -
Paul Streck,
Chief Medical Officer -
Eugene Jeffrey Sullivan,
Chief Medical Officer -
Myrtle S Potter,
Director -
Donald J Jr Hayden,
Director -
Geoffrey Allan,
President, CEO and Chairman -
Stephen C. Glover,
President Follow-on Biologics -
Doug Farrar,
Vice President, ITP -
Michael Duncan,
Principal Financial Officer -
Thomas A Keuer,
VP, ITP (Subsidiary) -
Philip J Young,
Chief Business Officer and EVP -
Ronald D Gunn,
Executive Vice President -
Mark Quigley,
Vice President, Quality -
Randall W Whitcomb,
Director -
Peggy Berry,
Vice President, Regulatory -
Renu Gupta,
Chief Medical Officer -
Richard S Kollender,
Director -
Matthew Pauls,
Chief Commercial Officer -
Llc Fmr,
10% owner -
Andrea Holtzman Drucker,
Senior V.P., General Counsel -
Nicholas A. Jr. La Bella,
Chief Scientific Officer -
Kenneth G Condon,
Director -
Kevin P Tully,
Executive VP & CFO -
Timothy Whitten,
President & CEO -
Graham K Crooke,
Director -
Nicholas Lee Gurreri,
Senior VP, Commercial Ops -
Dennis M Lanfear,
Director -
John Drayton Wise,
Chief Commercial Officer -
Michael Alexander Smith,
Chief Legal Officer